These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18986281)

  • 41. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Kunde J; Hanschmann A; Marre R; Suttorp N; Welte T;
    J Antimicrob Chemother; 2009 Jul; 64(1):159-62. PubMed ID: 19403654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
    Esposito S; Fiore M
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
    [No Abstract]   [Full Text] [Related]  

  • 43. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia.
    Barlow G; Nathwani D; Myers E; Sullivan F; Stevens N; Duffy R; Davey P
    J Antimicrob Chemother; 2008 Feb; 61(2):442-51. PubMed ID: 18065412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
    Tillotson GS; Echols RM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and microbiological end points in the treatment of pneumonia.
    Musher DM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S207-9. PubMed ID: 18986291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of guidelines on outcome: the evidence.
    Martínez R; Reyes S; Lorenzo MJ; Menéndez R
    Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of malnutrition on risk and outcome of community-acquired pneumonia.
    Loeb M; High K
    Respir Care Clin N Am; 2005 Mar; 11(1):99-108. PubMed ID: 15763225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.
    Daneman N; Low DE; McGeer A; Green KA; Fisman DN
    Clin Infect Dis; 2008 Apr; 46(8):1131-8. PubMed ID: 18444846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections.
    Granizo JJ; Aguilar L; Gimenez MJ; Coronel P; Gimeno M; Prieto J
    Rev Esp Quimioter; 2009 Jun; 22(2):57-61. PubMed ID: 19544097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials.
    Vouloumanou EK; Karageorgopoulos DE; Kazantzi MS; Kapaskelis AM; Falagas ME
    J Antimicrob Chemother; 2009 Jul; 64(1):16-24. PubMed ID: 19454521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe Q fever community-acquired pneumonia (CAP) mimicking Legionnaires' disease: Clinical significance of cold agglutinins, anti-smooth muscle antibodies and thrombocytosis.
    Cunha BA; Nausheen S; Busch L
    Heart Lung; 2009; 38(4):354-62. PubMed ID: 19577708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
    Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
    Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New guidelines for the management of adult community-acquired pneumonia.
    Armitage K; Woodhead M
    Curr Opin Infect Dis; 2007 Apr; 20(2):170-6. PubMed ID: 17496576
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature.
    Hatchette TF; Gupta R; Marrie TJ
    Clin Infect Dis; 2000 Dec; 31(6):1349-56. PubMed ID: 11096001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia.
    Metlay JP
    Infect Dis Clin North Am; 2004 Dec; 18(4):777-90. PubMed ID: 15555824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Community-acquired pneumonia in children].
    Gendrel D; Moulin F
    Rev Prat; 2007 Nov; 57(17):1883-94. PubMed ID: 18095624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.
    Kontou P; Kuti JL; Nicolau DP
    Am J Emerg Med; 2009 Oct; 27(8):968-74. PubMed ID: 19857416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?
    Talbot GH
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S180-5. PubMed ID: 18986286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.